Table 4 Fourth-generation EGFR TKIs under clinical investigation
From: Advances in molecular pathology and therapy of non-small cell lung cancer
Inhibitors | NCT numbers | Sponsors | Status |
|---|---|---|---|
BLU-945 | NCT04862780 | Blueprint Medicines Corporation | Phase I/II |
H002 | NCT05552781 | RedCloud Bio | Phase I/IIa |
JIN-A02 | NCT05394831 | J INTS Bio | PhaseI/II |
BPI-361175 | NCT05329298 | Betta Pharmaceuticals | Phase I/II |
WJ13404 | NCT05662670 | Suzhou Junjing BioSciences | Phase I/II |
QLH11811 | NCT05555212 | Qilu Pharmaceutical | Phase I |
TQB3804 | NCT04128085 | Chia Tai Tianqing Pharmaceutical Group | Phase I |
BBT-207 | NCT05920135 | Bridge Biotherapeutics, Inc. | PhaseI/II |
BDTX-1535 | NCT05256290 | Black Diamond Therapeutics, Inc. | Phase I/II |
HS-10375 | NCT05435248 | Jiangsu Hansoh Pharmaceutical | PhaseI/II |
TAS3351 | NCT05765734 | Taiho Oncology, Inc. | PhaseI/II |
WSD0922-FU | NCT06631989 | Wayshine Biopharm, Inc. | Phase I/II |
